Advanced Methodologies and Techniques for Assessing Nanomaterial Toxicity: From Manufacturing to Nanomedicine Screening

Nanotoxicology: Progress toward Nanomedicine

Volumn , Issue , 2014, Pages 155-176

  Prina Mello, Adriele ^a   Mohamed, Bashir M ^a   Verma, Navin K ^b   Jain, Namrata ^a   Volkov, Yuri ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b LEE KONG CHIAN SCHOOL OF MEDICINE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84963803427     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16562-16     Document Type: Chapter

References (71)

1. Liu, Y.; Solomon, M.; Achilefu, S. Perspectives and potential applications of nanomedicine in breast and prostate cancer. Medicinal Research Reviews 2013, 33, 3-32.
2. Chen, X.; Gambhir, S. S.; Cheon, J. Theranostic nanomedicine. Accounts of Chemical Research 2011, 44, 841.
3. Lammers, T.; Aime, S.; Hennink, W. E.; Storm, G.; Kiessling, F. Theranostic nanomedicine. Accounts of Chemical Research 2011, 44, 1029-1038.
4. Vizirianakis, I. S. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine: Nanotechnology, Biology, and Medicine 2011, 7, 11-17.
5. Grattoni, A.; Tasciotti, E.; Fine, D.; Fernandez-Moure, J. S.; Sakamoto, J.; Hu, Y.; Weiner, B.; Ferrari, M.; Parazynski, S. Nanotechnologies and regenerative medical approaches for space and terrestrial medicine. Aviation, Space, and Environmental Medicine 2012, 83, 1025-1036.
6. Prescott, C. Regenerative nanomedicines: An emerging investment prospective? Journal of the Royal Society, Interface 2010, 7 Suppl 6, S783-S787.
7. Seaton, A.; Tran, L.; Aitken, R.; Donaldson, K. Nanoparticles, human health hazard and regulation. Journal of the Royal Society, Interface 2010, 7 Suppl 1, S119-S129.
8. Naahidi, S.; Jafari, M.; Edalat, F.; Raymond, K.; Khademhosseini, A.; Chen, P., Biocompatibility of engineered nanoparticles for drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 2013, 166, 182-194.
9. Eaton, M. A. W. How do we develop nanopharmaceuticals under open innovation? Nanomedicine: Nanotechnology, Biology, and Medicine 2011, 7, 371-375.
10. Linkov, I.; Bates, M. E.; Canis, L. J.; Seager, T. P.; Keisler, J. M. A decision-directed approach for prioritizing research into the impact of nanomaterials on the environment and human health. Nature Nanotechnology 2011, 6, 784-787.
11. Linkov, I.; Satterstrom, F. K.; Corey, L. M. Nanotoxicology and nanomedicine: Making hard decisions. Nanomedicine: Nanotechnology, Biology, and Medicine 2008, 4, 167-171.
12. Potocnik, J. European Commission recommendation on the definition of nanomaterial. Official Journal of the European Union 2011, L275/38-L275/40, 3.
13. Dang, Y.; Zhang, Y.; Fan, L.; Chen, H.; Roco, M. C. Trends in worldwide nanotechnology patent applications: 1991 to 2008. Journal of Nanoparticle Research 2010, 12, 687-706.
14. Marshall, J., Draft guidelines for nanomedicine unveiled. Nature 2011, doi:10.1038 /news.2011.562. Available at: http://www.nature.com/news/2011/110928/full/news. 2011.562.html.
15. Reich, E. S. Nano rules fall foul of data gap. Nature 2011, 480, 160-161.
16. Schütz, C. A.; Juillerat-Jeanneret, L.; Mueller, H.; Lynch, I.; Riediker, M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013, 8, 449-467.
17. Movia, D.; Poland, C.; Tran, L.; Volkov, Y.; Prina-Mello, A. Multilayered nanoparticles for personalized medicine: Translation into clinical markets. In, Bawa, R.; Audette, G. F.; Rubinstein, I. eds. Handbook of Clinical Nanomedicine: From Bench to Bedside. Pan Stanford Publishing: Singapore, 2013; Vol. 1, p 17.
18. Join the dialogue. Nature Nanotechnology 2012, 7, 545. Available at: http://www.nature. com/nnano/journal/v7/n9/full/nnano.2012.150.html.
19. Schrurs, F.; Lison, D. Focusing the research efforts. Nature Nanotechnology 2012, 7, 546-548.
20. Hartung, T. Toxicology for the twenty-first century. Nature 2009, 460, 208-212.
21. Kievit, F. M.; Zhang, M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Accounts of Chemical Research 2011, 44, 853-862.
22. Ventola, C. L. The nanomedicine revolution: Part 1: Emerging concepts. P and T: A Peer-Reviewed Journal for Formulary Management 2012, 37, 512-525.
23. Hoffmann, S.; Cole, T.; Hartung, T., Skin irritation: Prevalence, variability, and regulatory classification of existing in vivo data from industrial chemicals. Regulatory Toxicology and Pharmacology Journal 2005, 41, 159-166.
24. Service, R. F. Nanotechnology. Can high-speed tests sort out which nanomaterials are safe? Science 2008, 321, 1036-1037.
25. Meng, H.; Xia, T.; George, S.; Nel, A. E. A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano 2009, 3, 1620-1627.
26. Höfer, T.; Gerner, I.; Gundert-Remy, U.; Liebsch, M.; Schulte, A.; Spielmann, H.; Vogel, R.; Wettig, K. Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Archives of Toxicology 2004, 78, 549-564.
27. Stone, V.; Johnston, H.; Schins, R. P. F. Development of in vitro systems for nanotoxicology: Methodological considerations. Critical Reviews in Toxicology 2009, 39, 613-626.
28. Jones, C. F.; Grainger, D. W. In vitro assessments of nanomaterial toxicity. Advanced Drug Delivery Reviews 2009, 61, 438-456.
29. Nel, A.; Xia, T.; Madler, L.; Li, N., Toxic potential of materials at the nanolevel. Science 2006, 311, 622-627.
30. Nanomedicine, E. T. P. O. Nanomedicine 2020 Contribution of Nanomedicine to Horizon 2020-White Paper to the Horizon 2020 framework programme for research and innovation-recommendation from the Nanomedicine community. 2013, 20.
31. Abraham, V. C.; Taylor, D. L.; Haskins, J. R. High content screening applied to large-scale cell biology. Trends in Biotechnology 2004, 22, 15-22.
32. Abraham, V. C.; Towne, D. L.; Waring, J. F.; Warrior, U.; Burns, D. J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. Journal of Biomolecular Screening 2008, 13, 527-537.
33. Towne, D. L.; Nicholl, E. E.; Comess, K. M.; Galasinski, S. C.; Hajduk, P. J.; Abraham, V. C. Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research. Journal of Biomolecular Screening 2012, 17, 1005-1017.
34. Ghosh, R. N.; Grove, L.; Lapets, O. A quantitative cell-based high-content screening assay for the epidermal growth factor receptor-specific activation of mitogen-activated protein kinase. Assay and Drug Development Technologies 2004, 2, 473-481.
35. Ghosh, R. N.; Chen, Y. T.; DeBiasio, R.; DeBiasio, R. L.; Conway, B. R.; Minor, L. K.; Demarest, K. T. Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. Bio Techniques 2000, 29, 170-175.
36. Ghosh, R. N.; Lapets, O.; Haskins, J. R. Characteristics and value of directed algorithms in high content screening. Methods in Molecular Biology (Clifton, N.J.) 2007, 356, 63-81.
37. Mohamed, B. M.; Feighery, C.; Williams, Y.; Davies, A.; Kelleher, D.; Volkov, Y.; Kelly, J.; Abuzakouk, M. The use of cellomics to study enterocyte cytoskeletal proteins in coeliac disease patients. Central European Journal of Biology 2008, 3, 258-267.
38. 2 nanoparticles exposure as an early indicator of cytotoxicity. Journal of Nanobiotechnology 2011, 9, 29.
39. Williams, Y.; Sukhanova, A.; Nowostawska, M.; Davies, A. M.; Mitchell, S.; Oleinikov, V.; Gun’ko, Y.; Nabiev, I.; Kelleher, D.; Volkov, Y. Probing cell-type-specific intracellular nanoscale barriers using size-tuned quantum dots. Small 2009, 5, 2581-2588.
40. Mohamed, B. M.; Movia, D.; Knyazev, A.; Langevin, D.; Davies, A. M.; Prina-Mello, A.; Volkov, Y. Citrullination as early-stage indicator of cell response to single-walled carbon nanotubes. Scientific Reports 2013, 3, doi:10.1038/srep01124.
41. Mohamed, B. M.; Verma, N. K.; Davies, A. M.; McGowan, A.; Crosbie-Staunton, K.; Prina-Mello, A.; Kelleher, D. et al. Citrullination of proteins: A common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine 2012, 7, 1181-1195.
42. Cooper, S. E. J.; Kennedy, N. P.; Mohamed, B. M.; Abuzakouk, M.; Dunne, J.; Byrne, G.; McDonald, G. et al. Immunological indicators of coeliac disease activity are not altered by long-term oats challenge. Clinical and Experimental Immunology 2013, 171, 313-318.
43. Healthy challenges. Nature Nanotechnology 2007, 2, 451, doi:10.1038/nnano.2007.258. Available at: URL: http://www.nature.com/nnano/journal/v2/n8/full/nnano.2007.258.html.
44. Jan, E.; Byrne, S. J.; Cuddihy, M.; Davies, A. M.; Volkov, Y.; Gun’ko, Y. K.; Kotov, N. A. High-content screening as a universal tool for fingerprinting of cytotoxicity of nanoparticles. ACS Nano 2008, 2, 928-938.
45. Prina-Mello, A.; Crosbie-Staunton, K.; Salas, G.; Del Puerto Morales, M.; Volkov, Y. Multiparametric toxicity evaluation of SPIONs by high content screening technique: Identification of biocompatible multifunctional nanoparticles for nanomedicine. IEEE Transactions on Magnetics 2013, 49, 377-382.
46. Murphy, F. A.; Poland, C. A.; Duffin, R.; Al-Jamal, K. T.; Ali-Boucetta, H.; Nunes, A.; Byrne, F. et al. Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura. American Journal of Pathology 2011, 178, 2587-2600.
47. Wagner, K.; Fach, B.; Kolar, R. Inconsistencies in data requirements of EU legislation involving tests on animals. Altex 2012, 29, 302-332.
48. Giaever, I.; Keese, C. R. Monitoring fibroblast behavior in tissue culture with an applied electric field. Proceedings of the National Academy of Sciences of the United States of America 1984, 81, 3761-3764.
49. Wegener, J.; Keese, C. R.; Giaever, I. Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. Experimental Cell Research 2000, 259, 158-166.
50. Luong, J. H.; Habibi-Rezaei, M.; Meghrous, J.; Xiao, C.; Male, K. B.; Kamen, A. Monitoring motility, spreading, and mortality of adherent insect cells using an impedance sensor. Analytical Chemistry 2001, 73, 1844-1848.
51. Arndt, S.; Seebach, J.; Psathaki, K.; Galla, H. J.; Wegener, J. Bioelectrical impedance assay to monitor changes in cell shape during apoptosis. Biosensors and Bioelectronics 2004, 19, 583-94.
52. Ghosh, P. M.; Keese, C. R.; Giaever, I. Monitoring electropermeabilization in the plasma membrane of adherent mammalian cells. Biophysical Journal 1993, 64, 1602-1609.
53. Giaever, I.; Keese, C. R. A morphological biosensor for mammalian cells. Nature 1993, 366, 591-592.
54. Verma, N. K.; Conroy, J.; Lyons, P. E.; Coleman, J.; O’Sullivan, M. P.; Kornfeld, H.; Kelleher, D.; Volkov, Y. Autophagy induction by silver nanowires: A new aspect in the biocompatibility assessment of nanocomposite thin films. Toxicology and Applied Pharmacology 2012, 264, 451-461.
55. Verma, N. K.; Moore, E.; Blau, W.; Volkov, Y.; Babu, P. R. Cytotoxicity evaluation of nanoclays in human epithelial cell line A549 using high content screening and real-time impedance analysis. Journal of Nanoparticle Research 2012, 14.
56. Verma, N. K.; Crosbie-Staunton, K.; Satti, A.; Gallagher, S.; Ryan, K. B.; Doody, T.; McAtamney, C. et al. Magnetic core-shell nanoparticles for drug delivery by nebulization. Journal of Nanobiotechnology 2013, 11, 1.
57. Lysaght, J.; Verma, N. K.; Maginn, E. N.; Ryan, J. M.; Campiani, G.; Zisterer, D. M.; Williams, D. C.; Browne, P. V.; Lawler, M. P.; McElligott, A. M. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells. International Journal of Oncology 2013, 42, 239-246.
58. Hondroulis, E.; Liu, C.; Li, C. Z. Whole cell based electrical impedance sensing approach for a rapid nanotoxicity assay. Nanotechnology 2010, 21, 315103.
59. Xiao, C.; Lachance, B.; Sunahara, G.; Luong, J. Assessment of cytotoxicity using electric cell-substrate impedance sensing: Concentration and time response function approach. Analytical Chemistry 2002, 74, 5748-5753.
60. Xiao, C.; Luong, J. H. T. Assessment of cytotoxicity by emerging impedance spectroscopy. Toxicology and Applied Pharmacology 2005, 206, 102-112.
61. Hug, T. S. Biophysical methods for monitoring cell-substrate interactions in drug discovery. Assay and Drug Development Technologies 2003, 1, 479-488.
62. Zhang, X. Q.; Xu, X.; Bertrand, N.; Pridgen, E.; Swami, A.; Farokhzad, O. C. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Advanced Drug Delivery Reviews 2012, 64, 1363-1384.
63. Ramachandran, S.; Lal, R. Scope of atomic force microscopy in the advancement of nanomedicine. Indian Journal of Experimental Biology 2010, 48, 1020-1036.
64. Samuel, S. P.; Jain, N.; O’Dowd, F.; Paul, T.; Kashanin, D.; Gerard, V. A.; Gun’ko, Y. K.; Prina-Mello, A.; Volkov, Y. Multifactorial determinants that govern nanoparticle uptake by human endothelial cells under flow. International Journal of Nanomedicine 2012, 7, 2943-2956.
65. Ramachandran, S.; Teran Arce, F.; Lal, R. Potential role of atomic force microscopy in systems biology. Wiley Interdisciplinary Reviews. Systems Biology and Medicine 2011, 3, 702-716.
66. Hinterdorfer, P.; Dufrene, Y. F. Detection and localization of single molecular recognition events using atomic force microscopy. Nature Methods 2006, 3, 347-355.
67. Dammer, U.; Hegner, M.; Anselmetti, D.; Wagner, P.; Dreier, M.; Huber, W.; Guntherodt, H. J. Specific antigen/antibody interactions measured by force microscopy. Biophysical Journal 1996, 70, 2437-2441.
68. McKendry, R.; Zhang, J.; Arntz, Y.; Strunz, T.; Hegner, M.; Lang, H. P.; Baller, M. K. et al. Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proceedings of the National Academy of Sciences of the United States of America 2002, 99, 9783-9788.
69. Almqvist, N.; Bhatia, R.; Primbs, G.; Desai, N.; Banerjee, S.; Lal, R. Elasticity and adhesion force mapping reveals real-time clustering of growth factor receptors and associated changes in local cellular rheological properties. Biophysical Journal 2004, 86, 1753-1762.
70. Hussain, S. M.; Hess, K. L.; Gearhart, J. M.; Geiss, K. T.; Schlager, J. J. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicology in Vitro 2005, 19, 975-983.
71. Schrand, A. M.; Lin, J. B.; Hussain, S. M. Assessment of cytotoxicity of carbon nanoparticles using 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium (MTS) cell viability assay. Methods in Molecular Biology (Clifton, N.J.) 2012, 906, 395-402.